Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Abstract Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world Taiwanese setting, incl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kao-Chi Chang, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Yung-Yu Hsieh, Wei-Ming Chen, Yi-Hsing Chen, Chun-Hsien Chen, Chi-Wei Yen, Huang-Wei Xu, Wei-Lin Tung, Chao-Hung Hung, Sheng-Nan Lu, Te-Sheng Chang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c3f883780e4f498eae4652d3f293f1fe
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares